Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29235195.
- Also identified by DOI 10.1002/stem.2754 and PMC identifier 5914526.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC-derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC-derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti-tumor activity and produced in essentially unlimited numbers. Stem Cells 2018;36:134-145.
Medical subject headings
- Immunotherapy
- Pluripotent Stem Cells